207 related articles for article (PubMed ID: 11304695)
1. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
2. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
3. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
4. Unique features of the mode of action of ET-743.
D'Incalci M; Erba E; Damia G; Galliera E; Carrassa L; Marchini S; Mantovani R; Tognon G; Fruscio R; Jimeno J; Faircloth GT
Oncologist; 2002; 7(3):210-6. PubMed ID: 12065793
[TBL] [Abstract][Full Text] [Related]
5. Role of homologous recombination in trabectedin-induced DNA damage.
Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
[TBL] [Abstract][Full Text] [Related]
6. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
7. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
9. ET-743: more than an innovative mechanism of action.
Scotto KW
Anticancer Drugs; 2002 May; 13 Suppl 1():S3-6. PubMed ID: 12173491
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
11. UV sensitivity and impaired nucleotide excision repair in DNA-dependent protein kinase mutant cells.
Muller C; Calsou P; Frit P; Cayrol C; Carter T; Salles B
Nucleic Acids Res; 1998 Mar; 26(6):1382-9. PubMed ID: 9490781
[TBL] [Abstract][Full Text] [Related]
12. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
14. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
15. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
[TBL] [Abstract][Full Text] [Related]
16. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
17. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
[TBL] [Abstract][Full Text] [Related]
19. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
